SpringerLink
Log in

UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is a novel anti-apoptotic gene, and overexpression of UHRF1 is involved in tumorigenicity. Here, immunohistochemistry was used to detect UHRF1 expression in non-muscle-invasive bladder cancer (NMIBC), and these data were examined for correlation with clinicopathological parameters and prognosis. The UHRF1 expression rate was 49.2% in a total of 118 bladder cancer tissues, which was significantly higher than in normal tissues, and UHRF1 expression has a significantly positive correlation with tumor grade (P = 0.027) and recurrence (P = 0.013). Survival analysis showed that UHRF1 high expression patients’ mean survival time (42.59 months) was significantly shorter than that (71.36 months) of UHRF1 low expression patients (P = 0.0002). Multivariate analysis showed that UHRF1 overexpression was an independent prognostic factor for tumor recurrence (P < 0.0001). So UHRF1 may be a molecular marker to predict the recurrence of NMIBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49.

    Article  PubMed  Google Scholar 

  2. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–49.

    Article  PubMed  CAS  Google Scholar 

  3. Reuter VE. Bladder. risk and prognostic factors—a pathologist’s perspective. Urol Clin North Am. 1999;26(3):481–92.

    Article  PubMed  CAS  Google Scholar 

  4. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163(1):73–8.

    Article  PubMed  CAS  Google Scholar 

  5. Muto M, Utsuyama M, Horiguchi T, et al. The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines. Cell Prolif. 1995;28(12):645–57.

    Article  PubMed  CAS  Google Scholar 

  6. Fujimori A, Matsuda Y, Takemoto Y, et al. Cloning and map** of Np95 gene which encodes a novel nuclear protein associated with cell proliferation. Mamm Genome. 1998;9(12):1032–5.

    Article  PubMed  CAS  Google Scholar 

  7. Uemura T, Kubo E, Kanari Y, et al. Temporal and spatial localization of novel nuclear protein NP95 in mitotic and meiotic cells. Cell Struct Funct. 2000;25(3):149–59.

    Article  PubMed  CAS  Google Scholar 

  8. Arima Y, Hirota T, Bronner C, et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition. Genes Cells. 2004;9(2):131–42.

    Article  PubMed  CAS  Google Scholar 

  9. Bonapace IM, Latella L, Papait R, et al. Np95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry. J Cell Biol. 2002;157(6):909–14.

    Article  PubMed  CAS  Google Scholar 

  10. Papait R, Pistore C, Negri D, et al. Np95 is implicated in pericentromeric heterochromatin replication and in major satellite silencing. Mol Biol Cell. 2007;18(3):1098–106.

    Article  PubMed  CAS  Google Scholar 

  11. Bostick M, Kim JK, Esteve PO, et al. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007;317(5845):1760–4.

    Article  PubMed  CAS  Google Scholar 

  12. Sharif J, Muto M, Takebayashi S, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007;450(7171):908–12.

    Article  PubMed  CAS  Google Scholar 

  13. Arita K, Ariyoshi M, Tochio H, et al. Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flip** mechanism. Nature. 2008;455(7214):818–21.

    Article  PubMed  CAS  Google Scholar 

  14. Avvakumov GV, Walker JR, Xue S, et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature. 2008;455(7214):822–5.

    Article  PubMed  CAS  Google Scholar 

  15. Qian C, Li S, Jakoncic J, et al. Structure and hemimethylated CpG binding of the SRA domain from human UHRF1. J Biol Chem. 2008;283(50):34490–4.

    Article  PubMed  CAS  Google Scholar 

  16. Achour M, Jacq X, Ronde P, et al. The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression. Oncogene. 2008;27(15):2187–97.

    Article  PubMed  CAS  Google Scholar 

  17. Jeanblanc M, Mousli M, Hopfner R, et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. Oncogene. 2005;24(49):7337–45.

    Article  PubMed  CAS  Google Scholar 

  18. Hopfner R, Mousli M, Jeltsch JM, et al. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase II alpha expression. Cancer Res. 2000;60(1):121–8.

    PubMed  CAS  Google Scholar 

  19. Mousli M, Hopfner R, Abbady AQ, et al. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells. Br J Cancer. 2003;89(1):120–7.

    Article  PubMed  CAS  Google Scholar 

  20. Unoki M, Nishidate T, Nakamura Y. ICBP90, an E2F–1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain. Oncogene. 2004;23(46):7601–10.

    Article  PubMed  CAS  Google Scholar 

  21. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V, et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology. 2005;129(5):1454–63.

    Article  PubMed  CAS  Google Scholar 

  22. Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol. 2005;36(10):1101–7.

    Article  PubMed  CAS  Google Scholar 

  23. Unoki M, Kelly JD, Neal DE, et al. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer. 2009;101(1):98–105.

    Article  PubMed  CAS  Google Scholar 

  24. Jenkins Y, Markovtsov V, Lang W, et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear RING finger protein, in tumor cell growth. Mol Biol Cell. 2005;16(12):5621–9.

    Article  PubMed  CAS  Google Scholar 

  25. Bronner C, Achour M, Arima Y, et al. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future? Pharmacol Ther. 2007;115(3):419–34.

    Article  PubMed  CAS  Google Scholar 

  26. Hussain SP, Harris CC. Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens. Mutat Res. 2000;462(2–3):311–22.

    PubMed  CAS  Google Scholar 

  27. Abbady AQ, Bronner C, Trotzier MA, et al. ICBP90 expression is downregulated in apoptosis-induced Jurkat cells. Ann N Y Acad Sci. 2003;1010:300–3.

    Article  PubMed  CAS  Google Scholar 

  28. Theodoropoulos VE, Lazaris AC, Kastriotis I, et al. Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU Int. 2005;95(3):425–31.

    Article  PubMed  CAS  Google Scholar 

  29. Dekairelle AF, Tombal B, Cosyns JP, Gala JL. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11(13):4724–32.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, Renji Hospital, School of Medicine Shanghai, Jiaotong University, No. 145 Shan Dong Middle Road, Shanghai, 200001, China

    Guo-Liang Yang, Lian-Hua Zhang, Juan-Jie Bo, Hai-Ge Chen, Ming Cao, Dong-Ming Liu & Yi-Ran Huang

Authors
  1. Guo-Liang Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lian-Hua Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan-Jie Bo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hai-Ge Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dong-Ming Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-Ran Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan-Jie Bo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, GL., Zhang, LH., Bo, JJ. et al. UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer. Med Oncol 29, 842–847 (2012). https://doi.org/10.1007/s12032-011-9983-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-9983-z

Keywords

Search

Navigation